Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Aegerion Discloses Juxtapid Marketing Subpoena

By Pharmaceutical Processing | January 10, 2014

NEW YORK (AP) — Aegerion Pharmaceuticals said Thursday that the U.S. government is looking into the marketing of its cholesterol disorder drug Juxtapid.

The company said it received a subpoena from the Department of Justice. The agency is seeking documents related to the marketing of Juxtapid in the U.S. Aegerion said it will cooperate fully with the investigation.

Juxtapid is designed to treat a rare condition called homozygous familial hypercholesterolemia, which causes high levels of “bad” LDL cholesterol. The Food and Drug Administration approved the drug in December 2012 and European Union regulators did the same in August 2013.

Aegerion also said it expects to report $48 million to $49 million in net product sales in 2013. That implies about $24 million to $25 million in revenue in the fourth quarter. The company said it expects to report $190 million to $210 million in revenue in 2014.

Shares of Aegerion Pharmaceuticals Inc. fell $10.75, or 14.6 percent, to $63 in aftermarket trading. The stock rose 52 cents to $73.75 during the day.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE